These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31625532)

  • 1. Changes in central and peripheral blood pressure parameters during antiangiogenic treatment of metastatic renal cell carcinoma.
    Lipski D; Uruski P; Tomczak P; Adamiak J; Ramlau R; Tykarski A
    Pol Arch Intern Med; 2019 Dec; 129(12):942-944. PubMed ID: 31625532
    [No Abstract]   [Full Text] [Related]  

  • 2. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypertension as predictive factor in renal cell cancer treated with antiangiogenic therapy].
    Gennari L; Belinsky J; Graziano C; Jankilevich G
    Medicina (B Aires); 2011; 71(3):207-10. PubMed ID: 21745767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies.
    George S; Rini BI
    Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S40-4. PubMed ID: 17239283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypertension and palmar plantar erythroderma. Management of adverse events of angiogenetic inhibitors in the treatment of renal cell carcinoma].
    Rolfes N; Lümmen G
    Urologe A; 2011 Nov; 50(11):1387-91. PubMed ID: 21800197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors.
    Dirix LY; Maes H; Sweldens C
    Ann Oncol; 2007 Jun; 18(6):1121-2. PubMed ID: 17586755
    [No Abstract]   [Full Text] [Related]  

  • 8. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
    Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 11. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma.
    Bukowski RM
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1403-11. PubMed ID: 12882625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home blood-pressure monitoring in patients receiving sunitinib.
    Azizi M; Chedid A; Oudard S
    N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
    [No Abstract]   [Full Text] [Related]  

  • 13. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.
    Caro J; Morales E; Gutierrez E; Ruilope LM; Praga M
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):215-6. PubMed ID: 23458595
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
    Teo M; Downey FP; McDermott RS
    Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
    [No Abstract]   [Full Text] [Related]  

  • 18. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
    Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
    Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
    Stadler WM; Kuzel T; Shapiro C; Sosman J; Clark J; Vogelzang NJ
    J Clin Oncol; 1999 Aug; 17(8):2541-5. PubMed ID: 10561320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.